Ketamine Depression Treatment Passes Another Trial, But Isn’t For Everyone

Researchers behind the ASPIRE trial want to take the drug even further. Their new goal is to have the drug approved to treat patients with major depressive disorder who have active suicidal ideation with intent.

 “This is a specific vulnerable subset of patients with major depressive disorder and is especially meaningful as these patients are commonly excluded from clinical trials,”
2019-10-10T05:32:14+00:00